Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series.

27 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

1. 2021 The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine resistance after kidney transplantation: A study with histopathologic evidenceCitations 13 · OpenAlex
2. 2025 Efficacy and safety of treatments in familial Mediterranean fever and its complications: a systematic review informing the EULAR/PReS recommendations for familial Mediterranean feverCitations 10 · OpenAlex
3. 2021 The use of anti-interleukin-1 agents and tumor necrosis factor-alpha inhibitors in renal transplant recipients.Citations 10 · OpenAlex
4. 2021 The Use of Anti-Interleukin-1 Agents and Tumor Necrosis Factor‐Alpha Inhibitors in Renal Transplant RecipientsCitations 10 · OpenAlex
5. 2021 The use of anti-interleukin-1 agents and tumor necrosis factor\u2010alpha inhibitors in renal transplant recipientsCitations 10 · OpenAlex
6. 2021 The use of anti-interleukin-1 agents and tumor necrosis factor-alpha inhibitors in renal transplant recipientsCitations 9 · OpenAlex
7. 2023 Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score–matched cohort studyCitations 8 · OpenAlex
8. 2023 Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score–matched cohort studyCitations 8 · OpenAlex
9. 2023 The safety of canakinumab in systemic juvenile idiopathic arthritis and autoinflammatory diseases in pediatric patients: a multicenter studyCitations 8 · OpenAlex
10. 2023 Efficacy and safety of interleukin-1 blockers in kidney transplant recipients with familial Mediterranean fever: a propensity score–matched cohort studyCitations 8 · OpenAlex